Clicky

VALEO PHARMA INC.CL.A(VP2)

Description: Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.


Keywords: Pharmaceutical Pain Medication Pain Management Asthma Orphan Drug Respiratory Therapy Acute Respiratory Distress Syndrome Soft Tissue Sarcoma Ocular Hypertension Deep Vein Thrombosis Dry Eye Disease Emergency Treatment Epinephrine Pulmonary Embolism Yondelis Muscarinic Antagonists Idiopathic Parkinson's Disease Openangle Glaucoma Amikacin Beta Adrenergic Agonists Long Acting Beta Adrenoceptor Agonist

Home Page: www.valeopharma.com

16667 Hymus Boulevard
Kirkland, QC H9H 4R9
Canada
Phone: 514 694 0150


Officers

Name Title
Mr. Kyle Steiger Senior VP & Chief Commercial Officer
Mr. Al Moghaddam B. Com. Cma Chief Executive Officer
Mr. Pascal Tougas Chief Financial Officer
Mr. Frédéric Dumais Director of Communications & Investor Relations
Mr. Guy-Paul Allard VP of Legal Affairs & Corporate Secretary
Mr. Jean Francois Fournier Head of Ophthalmology Business Unit

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0.0092
IPO Date:
Fiscal Year End: October
Full Time Employees: 70
Back to stocks